渤健

179.01
开盘价
181.46
市值
26.97B+
最高价
182.23
最低价
177.38
收盘价
NaN
成交量
315.49K+
市盈率
20.91
股息率
0.00%

渤健简介

Biogen,Inc.开发、生产和销售肿瘤、神经系统、免疫系统和血液系统疾病的创新疗法和药物,能够将科学发现转变为人类健康保健方面的进步,为治疗包括:多发性硬化症、非何杰金氏淋巴瘤、风湿性关节炎、克隆氏症、慢性淋巴性白血病、干癣病等多种疾病治疗药物的研发做出了突出贡献。该公由Charles Weissmann,Heinz Schaller,Kenneth Murray,Walter Gilbert和Phillip Allen Sharp于1978年创立,总部位于马萨诸塞州剑桥。

如何购买 渤健 (BIIB)

登录
1分钟开户

1分钟开户

仅需1分钟即可完成账户申请和验证。整个过程完全自助,支持 RockFlow App 和网页端操作。

充值资金

充值资金

账户验证完成后,您可以使用首选的支付方式向账户充值。

购买 BIIB

购买 BIIB

通过 RockFlow App 或网页端搜索 BIIB,输入您想要投资的金额,然后点击确认即可完成交易。

logo

Social

Download

google playapp store

© Rockalpha Limited. All Rights Reserved.

Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.